Ann: Quarterly Appendix 4C and Activities Report, page-27

NO#7

Method for Treating Inflammatory Disorders; United States Divisional Patent Application 17/662,866, Notice of
Allowance received from USPTO 15 May 24, with grant anticipated August 2024

IMO This is very valuable news IMO


-------------------------------------------------------------

Quarterly Calculation

Dimerix ended the quarter with cash of $22.1 million ($35.2 million at 31 March 2024),

with net operating cash outflows for the period of $13.3 million

($3.3 million net operating cash inflows in the prior quarter).

Cash outflow for the period predominately related to the trial costs of the Phase 3 FSGS Clinical Study, including significant one-off costs relating to completion of study milestones pre-agreed with IQVIA and in relation to opening new clinical sites globally.


Correct me if I am wrong .. this is my take..

Item 8.1 was a one off of $13,278,000

So it is incorrect to divide Item 8.4 by Item 8.1 to obtain Item 8.5 result !!

As 8.1 is a abnormally expenditure say DXB

We need to go back to previous Cash flow reports.. to what is a normal quarterly expend !